ANI Pharmaceuticals, Inc.
ANIP
$95.20
-$0.15-0.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 38.68% | 30.26% | 26.20% | 23.60% | 34.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.68% | 30.26% | 26.20% | 23.60% | 34.27% |
| Cost of Revenue | 39.65% | 42.04% | 37.85% | 35.84% | 39.65% |
| Gross Profit | 38.06% | 23.26% | 19.28% | 16.54% | 31.09% |
| SG&A Expenses | 61.68% | 52.81% | 46.65% | 50.39% | 42.38% |
| Depreciation & Amortization | 41.38% | 27.03% | 13.28% | 2.11% | 3.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.05% | 41.85% | 37.13% | 35.36% | 35.37% |
| Operating Income | -56.82% | -72.12% | -70.28% | -60.35% | 24.00% |
| Income Before Tax | -141.54% | -164.03% | -211.78% | -156.85% | 437.00% |
| Income Tax Expenses | -153.42% | -186.88% | -437.60% | -123.91% | 257.91% |
| Earnings from Continuing Operations | -137.80% | -159.21% | -198.63% | -152.99% | 623.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -137.80% | -159.21% | -198.63% | -152.99% | 623.65% |
| EBIT | -56.82% | -72.12% | -70.28% | -60.35% | 24.00% |
| EBITDA | -2.45% | -19.38% | -24.58% | -28.75% | 8.87% |
| EPS Basic | -162.64% | -177.09% | -231.87% | -201.07% | 346.25% |
| Normalized Basic EPS | -102.87% | -125.92% | -127.84% | -93.35% | 108.38% |
| EPS Diluted | -165.80% | -179.42% | -235.91% | -208.51% | 335.11% |
| Normalized Diluted EPS | -104.66% | -126.99% | -128.89% | -93.97% | 107.61% |
| Average Basic Shares Outstanding | 2.60% | 4.16% | 7.37% | 10.88% | 14.39% |
| Average Diluted Shares Outstanding | 2.74% | 3.43% | 6.68% | 10.78% | 15.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -3.65% | -2.69% | -2.01% | -2.89% | 1.19% |